SEARCH

SEARCH BY CITATION

Reference

  • 1
    Druker BJ,Guilhot F,O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355(23): 24082417.
  • 2
    Hochhaus A,O'Brien SG,Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009; 23(6): 10541061.
  • 3
    Kantarjian H,Shah NP,Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362(24): 22602270.
  • 4
    Saglio G,Kim DW,Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362(24): 22512259.
  • 5
    Hughes TP,Hochhaus A,Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 2010; 11;116(19): 37583765.
  • 6
    Marin D,Ibrahim AR,Lucas C, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 2012; 20;30(3): 232238.
  • 7
    Baccarani M,Cortes J,Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009; 27(35): 60416051.
  • 8
    National Comprehensive Cancer Network clinical practice guidelines in oncology: chronic myelogenous leukemia version 2. 2012.http://www.nccn.org/ NCCN Guidelines™ & Clinical Resources/ (enter in 20 Aug 2011).
  • 9
    Branford S,Cross NC,Hochhaus A, et al. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia 2006; 20(11): 19251930.
  • 10
    Branford S,Rudzki Z,Harper A, et al. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia 2003; 17(12): 24012409.
  • 11
    Kantarjian HM,Talpaz M,Cortes J, et al. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res 2003; 9(1): 160166.
  • 12
    Lange T,Bumm T,Otto S, et al. Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy. Haematologica 2004; 89(1): 4957.
  • 13
    Lima L,Bernal-Mizrachi L,Saxe D, et al. Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond. Cancer 2011; 117(6): 12451252.
  • 14
    Lundán T,Juvonen V,Mueller MC, et al. Comparison of bone marrow high mitotic index metaphase fluorescence in situ hybridization to peripheral blood and bone marrow real time quantitative polymerase chain reaction on the International Scale for detecting residual disease in chronic myeloid leukemia. Haematologica 2008; 93(2): 178185.
  • 15
    Ballestrero A,Cirmena G,Dominietto A, et al. Peripheral blood vs. bone marrow for molecular monitoring of BCR-ABL1 levels in chronic myelogenous leukemia, a retrospective analysis in allogeneic bone marrow recipients. Int J Lab Hematol 2010; 32(4): 387391.
  • 16
    Stock W,Yu D,Karrison T, et al. Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples. Int J Oncol 2006; 28(5): 10991103.
  • 17
    Vardiman JW,Harris NL,Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100(7): 22922302.
  • 18
    Branford S,Hughes TP,Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol 1999; 107(3): 587599.
  • 19
    Qin YZ,Liu YR,Zhu HH, et al. Different kinetic patterns of BCR-ABL transcript levels in imatinib-treated chronic myeloid leukemia patients after achieving complete cytogenetic response. Int J Lab Hematol 2008; 30(4): 317323.
  • 20
    Gabert J,Beillard E,van der Velden VH, et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – a Europe Against Cancer program. Leukemia 2003; 17(12): 23182357.
  • 21
    Martinelli G,Iacobucci I,Rosti G, et al. Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients. Ann Oncol 2006; 17(3): 495502.
  • 22
    Krämer A,Löffler H,Bergmann J,Hochhaus A,Hehlmann R. Proliferating status of peripheral blood progenitor cells from patients with BCR/ABL-positive chronic myelogenous leukemia. Leukemia 2001; 15(1): 6268.
  • 23
    Abe A,Minami Y,Hayakawa F, et al. Retention but significant reduction of BCR-ABL transcript in hematopoietic stem cells in chronic myelogenous leukemia after imatinib therapy. Int J Hematol 2008;88(5):471475.